SCHEMBL5136147

SCHEMBL5136147

CCCCn1c(CN(Cc2ccc(C)c(C)c2)Cc2ccc3c(c2)OCO3)cnc1-c1ccc(F)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.47
THRB P10828 1/20 0.42
HSP90AA1 P07900 2/20 0.40
HSP90AB1 P08238 2/20 0.40
F2R P25116 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
LMNA P02545 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CTSL P07711 2/20 0.37
KDM4E B2RXH2 2/20 0.37
MEN1 O00255 1/20 0.37
MAPT P10636 1/20 0.37
TSHR P16473 1/20 0.37
CASP1 P29466 1/20 0.37
KMT2A Q03164 1/20 0.37
HSD17B10 Q99714 1/20 0.37
UBE2M P61081 2/20 0.36
DCUN1D1 Q96GG9 2/20 0.36
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4766728 0.96 C5AR1 (0.51) C5AR1THRBHSP90AA1HSP90AB1F2R
SCHEMBL5135741 0.92 C5AR1 (0.48) C5AR1HSP90AA1HSP90AB1F2RSMN1; SMN2
SCHEMBL5147409 0.91 C5AR1 (0.54) C5AR1HSP90AA1HSP90AB1F2RSMN1; SMN2
SCHEMBL5149996 0.91 C5AR1 (0.49) C5AR1HSP90AA1HSP90AB1F2RSMN1; SMN2
SCHEMBL4764298 0.91 C5AR1 (0.57) C5AR1THRBHSP90AA1HSP90AB1F2R
SCHEMBL5137625 0.91 C5AR1 (0.47) C5AR1HSP90AA1HSP90AB1F2RSMN1; SMN2
SCHEMBL5216956 0.90 C5AR1 (0.48) C5AR1HSP90AA1HSP90AB1F2RSMN1; SMN2
SCHEMBL5135991 0.90 C5AR1 (0.56) C5AR1HSP90AA1HSP90AB1F2RSMN1; SMN2
SCHEMBL5134967 0.90 C5AR1 (0.46) C5AR1THRBHSP90AA1HSP90AB1F2R
SCHEMBL5135773 0.90 C5AR1 (0.48) C5AR1HSP90AA1HSP90AB1F2RSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed